Literature DB >> 17228865

Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.

James A Monn1, Steven M Massey, Matthew J Valli, Steven S Henry, Gregory A Stephenson, Mark Bures, Marc Hérin, John Catlow, Deborah Giera, Rebecca A Wright, Bryan G Johnson, Sherri L Andis, Ann Kingston, Darryle D Schoepp.   

Abstract

(-)-4-Amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate (LY389795, (-)-3) is a highly potent and selective agonist of metabotropic glutamate receptors 2 (mGlu2) and 3 (mGlu3). As part of our ongoing research program, we have prepared S-oxidized variants of (-)-3, compounds (-)-10, (+)-11 (LY404040), and (-)-12 (LY404039). Each of these chiral heterobicyclic amino acids displaced specific binding of the mGlu2/3 receptor antagonist 3H-2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (3H-LY341495) from membranes expressing recombinant human mGlu2 or mGlu3 and acted as potent agonists in cells expressing these receptor subtypes. Docking of the most potent of these derivatives, (+)-11, to mGlu2 revealed the possibility of an additional H-bond interaction between the sulfoxide oxygen of (+)-11 with tyrosine residue Y236. Pharmacokinetic analysis of mGlu active enantiomers (+)-11 and (-)-12 in rats showed each to be well absorbed following oral administration. Consistent with their mGlu2/3 agonist potency and pharmacokinetic properties, both (+)-11 and (-)-12 blocked phencyclidine-evoked ambulations in a dose-dependent manner, indicating their potential as nonclassical antipsychotic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17228865     DOI: 10.1021/jm060917u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  A Simple Representation of Three-Dimensional Molecular Structure.

Authors:  Seth D Axen; Xi-Ping Huang; Elena L Cáceres; Leo Gendelev; Bryan L Roth; Michael J Keiser
Journal:  J Med Chem       Date:  2017-08-08       Impact factor: 7.446

2.  Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist.

Authors:  Manuel Cajina; Megan Nattini; Dekun Song; Gennady Smagin; Erling B Jørgensen; Gamini Chandrasena; Christoffer Bundgaard; Dorthe Bach Toft; Xinyan Huang; Francine Acher; Dario Doller
Journal:  ACS Med Chem Lett       Date:  2013-12-12       Impact factor: 4.345

3.  Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.

Authors:  Stephen Lowe; Robert Dean; Bradley Ackermann; Kimberley Jackson; Fanni Natanegara; Shelby Anderson; James Eckstein; Eunice Yuen; Mosun Ayan-Oshodi; Mary Ho; David McKinzie; Kenneth Perry; Kjell Svensson
Journal:  Psychopharmacology (Berl)       Date:  2011-08-17       Impact factor: 4.530

4.  Recent Progress on the Stereoselective Synthesis of Cyclic Quaternary alpha-Amino Acids.

Authors:  Carlos Cativiela; Mario Ordóñez
Journal:  Tetrahedron Asymmetry       Date:  2009-01-30

5.  Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models.

Authors:  Michael P Johnson; Mark A Muhlhauser; Eric S Nisenbaum; Rosa M A Simmons; Beth M Forster; Kelly L Knopp; Lijuan Yang; Denise Morrow; Dominic L Li; Jeffrey D Kennedy; Steven Swanson; James A Monn
Journal:  Br J Pharmacol       Date:  2017-03-13       Impact factor: 8.739

Review 6.  Progress in structure based drug design for G protein-coupled receptors.

Authors:  Miles Congreve; Christopher J Langmead; Jonathan S Mason; Fiona H Marshall
Journal:  J Med Chem       Date:  2011-06-15       Impact factor: 7.446

7.  Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.

Authors:  Joanna M Wierońska; Katarzyna Stachowicz; Francine Acher; Tomasz Lech; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2011-09-28       Impact factor: 4.530

8.  In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Authors:  Linda M Rorick-Kehn; Bryan G Johnson; Karen M Knitowski; Craig R Salhoff; Jeffrey M Witkin; Kenneth W Perry; Kelly I Griffey; Joseph P Tizzano; James A Monn; David L McKinzie; Darryle D Schoepp
Journal:  Psychopharmacology (Berl)       Date:  2007-03-24       Impact factor: 4.415

9.  Photocatalytic three-component asymmetric sulfonylation via direct C(sp3)-H functionalization.

Authors:  Shi Cao; Wei Hong; Ziqi Ye; Lei Gong
Journal:  Nat Commun       Date:  2021-04-22       Impact factor: 14.919

10.  Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia.

Authors:  Kohnosuke Kinoshita; Motoki Ochi; Katsuya Iwata; Misako Fukasawa; Jun-Ichi Yamaguchi
Journal:  Pharmacol Res Perspect       Date:  2019-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.